Cardiovascular effects of statins, beyond lipid-lowering properties

Pharmacological Research

Volumn 88, Issue , 2014, Pages 12-19

  Mihos, Christos G ^a   Pineda, Andres M ^a   Santana, Orlando ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Cardiovascular disorders; Pleiotropic effects; Statins

Indexed keywords

ACETYL COENZYME A; ALDOSTERONE ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; EDIFOLIGIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANTIATHEROTHROMBOTIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTILIPIDEMIC ACTIVITY; AORTA STENOSIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CRITICAL LIMB ISCHEMIA; DOWN REGULATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; GRAFT FAILURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC HEART FAILURE; TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR DISORDERS; HEART DISEASES; PERIPHERAL ARTERIAL DISEASE;

CEREBROVASCULAR DISORDERS; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PERIPHERAL ARTERIAL DISEASE;

EID: 84906791819     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.02.009     Document Type: Review

References (104)

1. T.R. Pedersen, L. Wilhelmsen, O. Faergeman, T.E. Strandberg, G. Thorgeirsson, and L. Troedsson et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering Am J Cardiol 86 2000 257 262 (Pubitemid 30462217)
2. M. Pignone, C. Phillips, and C. Mulrow Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials Br Med J 321 2000 983 985
3. A. Tonkin, P. Aylward, D. Colquhoun, P. Glasziou, P. Harris, and D. Hunt et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357 (Pubitemid 28509344)
4. C.G. Mihos, M.J. Salas, and O. Santana The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol Rev 18 2010 298 304
5. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118 (Pubitemid 40261799)
6. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 23 Suppl. 1 2004 III39 III43
7. C.G. Mihos, and O. Santana Pleiotropic effects of the HMG-CoA reductase inhibitors Int J Gen Med 4 2011 261 271
8. C.G. Mihos, R.T. Artola, and O. Santana The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review Rheumatol Int 32 2012 287 294
9. D. Yanuck, C.G. Mihos, and O. Santana Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review Int J Neurosci 122 2012 619 629
10. M.V. Cohen, X.M. Yang, and J.M. Downey Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies Cardiovasc Res 70 2 2006 231 239 (Pubitemid 44316808)
11. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 47 1998 1129 1135 (Pubitemid 28152885)
12. R. Scalia, M.E. Gooszen, S.P. Jones, M. Hoffmeyer, D.M. Rimmer, and S.D. Trocha et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in Apo E deficient mice Circulation 103 2001 2598 2603 (Pubitemid 32521971)
13. S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, and A.T. Baumer et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo Arterioscler Thromb Vasc Biol 22 2002 300 305 (Pubitemid 34127043)
14. Y. Rikitake, and J.K. Liao Rho GTPases, statins, and nitric oxide Circ Res 97 12 2005 1232 1235
15. S. Lemoine, L. Zhu, D. Legallois, M. Massetti, A. Manrique, and J.L. Hanouz Atorvastatin-induced cardioprotection of human myocardium is mediated by the inhibition of mitochondrial permeability transition pore opening via tumor necrosis factor-α and Janus kinase/signal transducers and activators of transcription pathway Anesthesiology 118 6 2013 1373 1384
16. S. Sanada, H. Asanuma, T. Minamino, K. Node, S. Takashima, and H. Okuda et al. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase Circulation 110 15 2004 2143 2149 (Pubitemid 39372492)
17. N.V. Solenkova, V. Solodushko, M.V. Cohen, and J.M. Downey Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt Am J Physiol Heart Circ Physiol 290 1 2006 H441 H449
18. D.J. Hausenloy, and D.M. Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res 61 3 2004 448 460 (Pubitemid 38210151)
19. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, and D.J. Lefer et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
20. C.A. Efthymiou, M.M. Mocanu, and D.M. Yellon Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling J Cardiovasc Pharmacol 45 3 2005 247 252 (Pubitemid 40328147)
21. K. Mensah, M.M. Mocanu, and D.M. Yellon Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45 8 2005 1287 1291 (Pubitemid 40523151)
22. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, and D.E. Casey Jr. et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 10 123 2011 e426 e579
23. R.S. Rosenson, and A.S. Brown Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence Curr Opin Lipidol 13 2002 625 630 (Pubitemid 36009201)
24. A. Link, T. Ayadhi, M. Böhm, and G. Nickenig Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome Eur Heart J 27 2006 2945 2955 (Pubitemid 44950437)
25. S.E. Nissen, S.J. Nicholls, I. Sipahi, P. Libby, J.S. Raichlen, and C.M. Ballantyne et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial J Am Med Assoc 295 2006 1556 1565
26. J. Rodés-Cabau, J.C. Tardif, M. Cossette, O.F. Bertrand, R. Ibrahim, and E. Larose et al. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome Am J Cardiol 104 2009 750 757
27. K.K. Ray, C.P. Cannon, C.H. McCabe, R. Cairns, A.M. Tonkin, and F.M. Sacks et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 2005 1405 1410 (Pubitemid 41446173)
28. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, and D. Waters et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial J Am Med Assoc 285 2001 1711 1718 (Pubitemid 32259905)
29. G. Patti, C.P. Cannon, S.A. Murphy, S. Mega, V. Pasceri, and C. Briguori et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies Circulation 123 2011 1622 1632
30. G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, and A. Montinaro Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J Am Coll Cardiol 54 2009 558 565
31. M.J. Lipinski, C.A. Cauthen, G.G. Biondi-Zoccai, A. Abbate, B. Vrtovec, and B.V. Khan et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure Am J Cardiol 104 2009 1708 1716
32. L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Zou, and J. Ge Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials Clin Cardiol 34 2011 117 123
33. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, and R. Latini et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
34. J. Kjekshus, E. Apetrei, V. Barrios, M. Böhm, J.G. Cleland, and J.H. Cornel et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261 (Pubitemid 350190755)
35. J.J. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, A. Hjalmarson, and H. Wedel et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
36. U. Mühlhäuser, O. Zolk, T. Rau, F. Münzel, T. Wieland, and T. Eschenhagen Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits FASEB J 20 2006 785 787 (Pubitemid 46671215)
37. K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res 62 2004 105 111 (Pubitemid 38326816)
38. L. Fauchier, N. Clementy, and D. Babuty Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Curr Opin Cardiol 28 2013 7 18
39. W.T. Fang, H.J. Li, H. Zhang, and S. Jiang The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials Br J Clin Pharmacol 74 2012 744 756
40. S. Negi, I. Shukrullah, E. Veledar, H.L. Bloom, D.P. Jones, and S.C. Dudley Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial) J Cardiovasc Electrophysiol 22 2011 414 419
41. C.M. Welzig, H.J. Park, J. Naggar, D. Confalone, J. Rhofiry, and J. Shea et al. Differential effects of statins (pravastatin or simvastatin) on ventricular ectopic complexes: Galpha(i2), a possible molecular marker for ventricular irritability Am J Cardiol 105 2010 1112 1117
42. A.K. Vyas, H. Guo, A.J. Moss, B. Olshansky, S.A. McNitt, and W.J. Hall et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II J Am Coll Cardiol 47 2006 769 773 (Pubitemid 43243099)
43. J. Buber, I. Goldenberg, A.J. Moss, P.J. Wang, S. McNitt, and W.J. Hall et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) J Am Coll Cardiol 60 2012 749 755
44. H. Desai, W.S. Aronow, C. Ahn, K. Gandhi, S. Hussain, and H.M. Lai et al. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure Am J Cardiol 105 2010 1336 1338
45. J.B. van Rees, C.J. Borleffs, M.K. de Bie, T. Stijnen, L. van Erven, and J.J. Bax et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality J Am Coll Cardiol 57 2011 556 562
46. W. Dichtl, T. Wolber, U. Paoli, S. Brüllmann, M. Stühlinger, and T. Berger et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients Clin Cardiol 34 2011 433 436
47. C.M. Otto Calcific aortic stenosis - time to look more closely at the valve N Engl J Med 359 2008 1395 1398
48. K.D. O'Brien Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more) Arterioscler Thromb Vasc Biol 26 2006 1721 1728 (Pubitemid 44305324)
49. C.E. Tourmousoglou, S. Lalos, and T. Psarros Do statins slow the progression of aortic valve stenosis Interact Cardiovasc Thorac Surg 7 2008 684 689
50. L.M. Moura, S.F. Ramos, J.L. Zamorano, I.M. Barros, L.F. Azevedo, and F. Rocha-Gonçalves et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis J Am Coll Cardiol 49 2007 554 561 (Pubitemid 46177435)
51. A.B. Rossebø, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, and K. Egstrup et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
52. K.L. Chan, K. Teo, J.G. Dumesnil, A. Ni, and J. Tam Effect of lipid lowering with rosuvastatin on progression of aortic stensosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial Circulation 121 2010 306 314
53. S.J. Cowell, D.E. Newby, R.J. Prescott, P. Bloomfield, J. Reid, and D.B. Northridge et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis N Engl J Med 352 2005 2389 2397 (Pubitemid 40958435)
54. W. Dichtl, H.F. Alber, G.M. Feuchtner, F. Hintringer, M. Reinthaler, and T. Bartel et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg) Am J Cardiol 102 2008 743 748
55. K.K. Teo, D.J. Corsi, J.W. Tam, J.G. Dumesnil, and K.L. Chan Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients Can J Cardiol 27 2011 800 808
56. D. van der Linde, S.C. Yap, A.P. van Dijk, W. Budts, P.G. Pieper, and P.H. van der Burgh et al. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial) Am J Cardiol 108 2011 265 271
57. F. Robicsek, M.J. Thubrikar, J.W. Cook, and B. Fowler The congenitally bicuspid aortic valve: how does it function? Why does it fail Ann Thorac Surg 77 2004 177 185 (Pubitemid 38130007)
58. M.K. Reriani, S.M. Dunlay, B. Gupta, C.P. West, C.S. Rihal, and L.O. Lerman et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials Eur J Cardiovasc Prev Rehabil 18 2011 704 716
59. S. Rajagopalan, I. Mckay, I. Ford, P. Bachoo, M. Greaves, and J. Brittenden Platelet activation increases the severity of peripheral arterial disease: implications for clinical management J Vasc Surg 46 2007 485 490 (Pubitemid 47371064)
60. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions J Vasc Surg 45 2007 645 654
61. A. Schanzer, N. Hevelone, C.D. Owens, J.A. Beckman, M. Belkin, and M.S. Conte Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia J Vasc Surg 47 2008 774 781
62. K.A. Giles, F. Pomposelli, A. Hamdan, M. Wyers, A. Jhaveri, and M.L. Schermerhorn Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair J Vasc Surg 49 2009 543 550
63. M. Schweitzer, B. Mitmaker, D. Obrand, N. Sheiner, C. Abraham, and S. Dostanic et al. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms Vasc Endovascular Surg 44 2010 116 122
64. H. Takagi, H. Yamamoto, K. Iwata, S. Goto, and T. Umemoto Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies Eur J Vasc Endovasc Surg 44 2012 287 292
65. C.P. Twine, and I.M. Williams Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms Br J Surg 98 2011 346 353
66. E.C. Jauch, J.L. Saver, H.P. Adams Jr., A. Bruno, J.J. Connors, and B.M. Demaerschalk et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 44 2013 870 947
67. L.B. Goldstein, C.D. Bushnell, R.J. Adams, L.J. Appel, L.T. Braun, and S. Chaturvedi et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 517 584
68. T. Sugawara, R. Ayer, and J.H. Zhang Role of statins in cerebral vasospasm Acta Neurochir Suppl (Wien) 104 2008 287 290
69. L. Sironi, M. Cimino, U. Guerrini, A.M. Calvio, B. Lodetti, and M. Asdente et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage Arterioscler Thromb Vasc Biol 23 2003 322 327 (Pubitemid 36231947)
70. P.A. Lapchak, and M.K. Han The 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits Brain Res 1303 2009 144 150
71. P. Sterzer, F. Meintzschel, A. Rosler, H. Lanfermann, H. Steinmetz, and M. Sitzer Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease Stroke 32 2001 2817 2820 (Pubitemid 33134471)
72. J. Chen, Z.G. Zhang, Y. Li, Y. Wang, L. Wang, and H. Jiang et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Ann Neurol 53 2003 743 751 (Pubitemid 36622511)
73. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
74. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, and A.E. Rudolph et al. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 556
75. L.B. Goldstein, P. Amarenco, M. Szarek, A. Callahan 3rd, M. Hennerici, and H. Sillesen et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study Neurology 70 2008 2364 2370
76. M.D. Vergouwen, R.J. de Haan, M. Vermeulen, and Y.B. Roos Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease Stroke 39 2008 497 502 (Pubitemid 351619482)
77. D. Woo, L.R. Sauerbeck, B.M. Kissela, J.C. Khoury, J.P. Szaflarski, and J. Gebel et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study Stroke 33 2002 1190 1195 (Pubitemid 34517033)
78. F. Marino, L. Guasti, M. Cosentino, M. Ferrari, E. Rasini, and R.C. Maio et al. Angiotensin II type I receptor expression in polymorphonuclear lymphocytes from high-risk subjects: changes after treatment with simvastatin J Cardiovasc Pharmacol 49 2007 299 305 (Pubitemid 46855124)
79. M. Siński, J. Lewandowski, A. Ciarka, J. Bidiuk, P. Abramczyk, and A. Dobosiewicz et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension Kardiol Pol 67 2009 613 620
80. B.A. Golomb, J.E. Dimsdale, H.L. White, J.B. Ritchie, and M.H. Criqui Reduction in blood pressure with statins: results from the UCSD statin study, a randomized trial Arch Intern Med 168 2008 721 727 (Pubitemid 351563955)
81. P. Strazzullo, S.M. Kerry, A. Barbato, M. Versiero, L. D'Elia, and F.P. Cappuccio Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials Hypertension 49 2007 792 798 (Pubitemid 351664226)
82. M. Banach, S. Nikfar, R. Rahimi, A. Bielecka-Dabrowa, M.J. Pencina, and D.P. Mikhailidis et al. The effects of statins on blood pressure in normotensive or hypertensive subjects - a meta-analysis of randomized controlled trials Int J Cardiol 168 2013 2816 2824
83. O.J. Liakopoulos, Y.H. Choi, P.L. Haldenwang, J. Strauch, T. Wittwer, and H. Dörge et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients Eur Heart J 29 2008 1548 1559 (Pubitemid 351881985)
84. J.A. Magovern, R.J. Moraca, S.H. Bailey, D.A. Dean, K.A. Simpson, and T.D. Maher et al. Preoperative statin is associated with decreased operative mortality in high-risk coronary artery bypass patients J Card Surg 5 2010 8
85. S. Khanal, N. Attallah, D.E. Smith, E. Kline-Rogers, D. Share, and M.J. O'Donnell et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions Am J Med 118 2005 843 849 (Pubitemid 41097461)
86. G. Patti, A. Nusca, M. Chello, V. Pasceri, A. D'Ambrosio, and G.W. Vetrovec et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention Am J Cardiol 101 2008 279 285 (Pubitemid 351162953)
87. F. Antonini-Canterin, L.M. Moura, R. Enache, E. Leiballi, D. Pavan, and R. Piazza et al. Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease Circulation 121 2010 2130 2136
88. A. Pineda, and L.X. Cubeddu Statin rebound or withdrawal syndrome: does it exist Curr Atheroscler Rep 13 2011 23 30
89. R.S. Rosenson Current overview of statin-induced myopathy Am J Med 116 2004 408 416 (Pubitemid 38299486)
90. C.C. Yang, S.S. Jick, and H. Jick Lipid-lowering drugs and the risk of depression and suicidal behavior Arch Intern Med 163 2003 1926 1932 (Pubitemid 37082704)
91. R.M. Guthrie, and D.R. Martin The safety of rosuvastatin: effects on renal and hepatic function Expert Opin Drug Saf 6 2007 573 581 (Pubitemid 351308215)
92. E. Björnsson, E.I. Jacobsen, and E. Kalaitzakis Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing J Hepatol 56 2012 374 380
93. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, and D.D. Waters et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis J Am Med Assoc 305 2011 2556 2564
94. A. Kashani, C.O. Phillips, J.M. Foody, Y. Wang, S. Mangalmurti, and D.T. Ko et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797 (Pubitemid 46018281)
95. Liakopoulos OJ. Statin Recapture Therapy Before Coronary Artery Bypass Grafting (StaRT-CABG). University of Cologne. ClinicalTrials.gov ID: NCT01715714.
96. Huo Y. Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI (ISCAP). Peking University First Hospital. ClinicalTrials.gov ID: NCT01293097.
97. Colombo A. Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention. IRCCS San Raffaele Monte Tabor. ClinicalTrials.gov ID: NCT01526460.
98. Matsumoto M. Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS. Hiroshima University Hospital. ClinicalTrials.gov ID: NCT00361699.
99. Kang SM. A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients. Severance Cardiovascular hospital, Yonsei University College of Medicine. ClinicalTrials.gov ID: NCT01127945.
100. Toso A. Impact of Early High-dose Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury in Unselected Patients With Non- ST Elevation Acute Coronary Syndromes Scheduled for Early Invasive Strategy. Prato Hospital. ClinicalTrials.gov ID: NCT01870804.
101. Sheldon RS. Statin Induced Regression of Cardiomyopathy Trial - SirCat. University of Calgary. ClinicalTrials.gov ID: NCT00317967.
102. Pereria SB. Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery. Hospital do Coração. ClinicalTrials.gov ID: NCT01543555.
103. Van Gelder IC. Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3. University Medical Centre Groningen. ClinicalTrials.gov ID: NCT00877643.
104. Montaner J. Multicentric, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Simvastatin in the Acute Phase of Ischemic Stroke. Hospital Universitari Vall d'Hebron Research Institute. ClinicalTrials.gov ID: NCT01073007.